Search for a trial

Short-term Efficacy of Stellate Ganglion Block to reduce Hot Flushes in women

To assess the short-term efficacy of stellate ganglion block on hot flush reduction versus sham procedure

Randomized double blind multi-centre study of the effects on low-dose pegvisomant treatment in acromegalic subjects in whom the IGF1 levels has been normalized by long-acting somatostatin analogues

Primary Study Objective:To assess the efficacy and safety of the co-administration of low-dose pegvisomant (40 mg, administered via subcutaneous injection given once a week) and long-acting somatostatin analogs (administered once monthly) on the…

A randomized, double-blind, multicenter, phase III study to evaluate the efficacy and safety of pasireotide LAR in patients with Cushing*s disease

To assess the efficacy and safety of two Pasireotide LAR regimens in CD patients.

A Phase 3, Multicenter Study Designed to Evaluate the Efficacy and Safety of a Long Acting hGH Product (MOD-4023) in Adult Subjects with Growth Hormone Deficiency

Primary objective:* Demonstrating clinical superiority of MOD-4023 compared to placebo in terms of reduction of fat mass (FM) in adults persons with GHDSecondary objectives:* Determining the efficacy of MOD-4023 compared to placebo in other body…

A Phase 3, Randomized, Double-­Blind, Placebo-­Controlled, Multicenter Study to Evaluate Efficacy and Safety of Octreotide Capsules in Patients Who Previously Tolerated and Demonstrated Biochemical Control on Injectable Somatostatin Receptor Ligands (SRL) Treatment

- To assess maintenance of biochemical control with octreotide capsules compared to placebo in patients with acromegaly, who previously demonstrated biochemical control on SRLs.- To assess maintenance of biochemical control, based on GH, with…

foresiGHt: A multicenter, randomized, parallel-arm, placebo- controlled (double- blind) and active-controlled (open-label) trial to compare the efficacy and safety of once-weekly lonapegsomatropin with placebo and a daily somatropin product in adults with growth hormone deficiency

Primary: To evaluate the efficacy of once-weekly lonapegsomatropin compared to placebo at 38 weeks in adults with growth hormone deficiency (GHD). Secondary: 1. To evaluate the safety and tolerability of once-weekly lonapegsomatropin in adults with…

A randomized placebo-controlled study in patients with a Gallium-68 DOTATATE PET/CT positive, clinically non-functioning pituitary macroadenoma (NFMA) of the effect of Lanreotide autosolution on Tumor (adenoma) size

To investigate the efficacy of lanreotide therapy as compared to placebo in patients with NFMA and positive pituitary somatostatin receptor imaging using Gallium-68 DOTATATE PET/CT, on tumor size.